CCCC
NASDAQ · Biotechnology
C4 Therapeutics Inc
$3.63
-0.05 (-1.36%)
Open$3.69
Previous Close$3.68
Day High$3.79
Day Low$3.48
52W High$3.95
52W Low$1.21
Volume—
Avg Volume3.84M
Market Cap393.62M
P/E Ratio—
EPS$-1.36
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+981.0% upside
Current
$3.63
$3.63
Target
$39.24
$39.24
$29.92
$39.24 avg
$50.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 47.02M | 44.80M | 17.10M |
| Net Income | -137,343,858 | -117,779,392 | 3.03M |
| Profit Margin | -292.1% | -277.5% | 17.7% |
| EBITDA | -148,165,678 | -134,118,527 | 5.37M |
| Free Cash Flow | — | — | 3.54M |
| Rev Growth | +5.0% | +5.0% | +6.2% |
| Debt/Equity | — | — | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |